Target Name: CCN6
NCBI ID: G8838
Review Report on CCN6 Target / Biomarker Content of Review Report on CCN6 Target / Biomarker
CCN6
Other Name(s): WISP-3 | Cellular communication network factor 6 | PPD | WNT1 inducible signaling pathway protein 3 | LIBC | Wnt1 signaling pathway protein 3 | cellular communication network factor 6 | PPAC | Cellular communication network factor 6 (isoform 1) | WNT1-inducible-signaling pathway protein 3 | PPRD | WISP3 | epididymis secretory sperm binding protein | CCN6 variant 1 | CCN6_HUMAN | Cellular communication network factor 6, transcript variant 1 | CCN family member 6

CCN6: A Potential Drug Target and Biomarker

C谩ntabroga cuadrada normal (CCN6) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the WISP family of proteins, which are known for their role in cell signaling. While the exact function of CCN6 is not yet well understood, research has shown that it plays an important role in several physiological processes, including inflammation, fibrosis, and autophagy.

Drug Targeting

As a potential drug target, CCN6 has been identified as a potential target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the main reasons for the potential targeting of CCN6 is its unique structure, which allows it to interact with a variety of molecules.

For example, CCN6 has been shown to interact with the protein PDGF-BB, which is a key signaling molecule in the development and progression of cancer. This interaction suggests that CCN6 may be a useful target for cancer therapies that target PDGF signaling.

Another potential target for CCN6 is its role in fibrosis. Fibrosis is a condition in which tissues become stiff and fibrotic, leading to pain, decreased mobility, and other serious health problems. CCN6 has been shown to play a role in the regulation of extracellular matrix (ECM) formation, which is a key step in the fibrotic process. Therefore, inhibiting CCN6 activity may be a promising approach for treating fibrosis.

In addition to its potential targets, CCN6 has also been shown to be a potential biomarker for several diseases, including neurodegenerative disorders and cancer. The presence of CCN6 in the brains of individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, suggests that it may be a useful biomarker for these conditions. Similarly, the presence of CCN6 in various tissues of individuals with cancer also suggests that it may be a useful biomarker for cancer.

Conclusion

In conclusion, CCN6 is a protein that has been shown to play an important role in several physiological processes, including inflammation, fibrosis, and autophagy. Its unique structure and potential interactions with key molecules make it an attractive target for drug development. While further research is needed to fully understand its function and potential targets, the potential of CCN6 as a drug target and biomarker is significant.

Protein Name: Cellular Communication Network Factor 6

Functions: Plays a role in mitochondrial electron transport and mitochondrial respiration (PubMed:27252383). Through its regulation of the mitochondrial function may play a role in normal postnatal skeletal growth and cartilage homeostasis (PubMed:27252383, PubMed:10471507)

The "CCN6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCN6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226